Concomitant tricuspid valve ring annuloplasty during mitral valve surgery : A systematic review and meta-analysis of clinical studies
Presented During:
Thursday, May 4, 2023: 6:30PM - Saturday, May 6, 2023: 2:29AM
New York Hilton Midtown
Posted Room Name:
Grand Ballroom Foyer
Abstract No:
MP013
Submission Type:
Abstract Submission
Authors:
Shi Sum Poon (1), YASIR AHMED (2), Umair Aslam (3), Vincenzo Cianci (4), Sobaran Sharma (3), Pankaj Kumar (3)
Institutions:
(1) N/A, United Kingdom, (2) N/A, SWANSEA, United Kingdom, (3) Morriston Hospital, Swansea, Wales, (4) Morriston Hospital, Swansea, NA
Submitting Author:
Shi Sum Poon
-
Contact Me
N/A
N/A
Co-Author(s):
YASIR AHMED
-
Contact Me
N/A
N/A
Umair Aslam
-
Contact Me
Morriston Hospital
Morriston Hospital
Vincenzo Cianci
-
Contact Me
Morriston Hospital
Morriston Hospital
Sobaran Sharma
-
Contact Me
Morriston Hospital
Morriston Hospital
Pankaj Kumar
-
Contact Me
Morriston Hospital
Morriston Hospital
Presenting Author:
Shi Sum Poon
-
Contact Me
N/A
N/A
Abstract:
Objective: Tricuspid valve regurgitation (TR) is common in patients with severe mitral valve disease and operative management of moderate TR is contentious. The decision as to whether to perform concomitant tricuspid valve ring annuloplasty for patients with moderate TR or less-than-moderate TR with a dilated TV annulus at the time of mitral valve surgery remains a contentious topic. A meta-analysis was performed to assess the clinical outcomes of concomitant tricuspid valve ring annuloplasty during mitral valve surgery.
Methods: A meta-analysis of comparative studies including mitral valve ( MV) surgery only versus MV surgery and concomitant TV ring annuloplasty (TVA). Primary outcome included in-hospital mortality, TR progression, and PPM implantation rate. Secondary outcome included re-operation for TR (at longest follow up available). Fixed-effect analysis was performed using pooled odd ratios (OR) via RevMan in accordance to Cochrane protocol and PRISMA guidelines.
Results: 8 studies met the eligibility criteria (2 RCTs, 6 cohort studies) with 1941 patients included in the final analysis (1090 patients in MV + TVA, 851 in MV only). The in-hospital mortality was comparable between the two groups ( 3.0% vs. 3.7%, OR=0.79, p=0.38). MV and concomitant TVA is associated with fewer moderate/severe TR progression (3.0% vs. 9.6% OR=0.29 ( 95% CI 0.15-0.55) p=0.0001). The rate of PPM implantation is higher in MV +TVA group although this did not reach statistical significance. (7.6% vs 5.3% OR=1.30 (95% CI 0.85-1.98) p=0.23). No significant difference in rate of re-operation between the two groups was detected.
Conclusions: Concomitant tricuspid valve ring annuloplasty during mitral valve surgery can be safely performed without increasing mortality and morbidity risks. There is a tendency for increased rate of PPM implantation in concomitant TVA although this did not reach statistical significance. Concomitant TVA is associated with a significantly lower incidence of post-operative moderate/severe TR progression. Further prospective and RCT studies are needed to evaluate the impact of concomitant TVA on right ventricular function and long term clinical benefits.
Methods: A meta-analysis of comparative studies including mitral valve ( MV) surgery only versus MV surgery and concomitant TV ring annuloplasty (TVA). Primary outcome included in-hospital mortality, TR progression, and PPM implantation rate. Secondary outcome included re-operation for TR (at longest follow up available). Fixed-effect analysis was performed using pooled odd ratios (OR) via RevMan in accordance to Cochrane protocol and PRISMA guidelines.
Results: 8 studies met the eligibility criteria (2 RCTs, 6 cohort studies) with 1941 patients included in the final analysis (1090 patients in MV + TVA, 851 in MV only). The in-hospital mortality was comparable between the two groups ( 3.0% vs. 3.7%, OR=0.79, p=0.38). MV and concomitant TVA is associated with fewer moderate/severe TR progression (3.0% vs. 9.6% OR=0.29 ( 95% CI 0.15-0.55) p=0.0001). The rate of PPM implantation is higher in MV +TVA group although this did not reach statistical significance. (7.6% vs 5.3% OR=1.30 (95% CI 0.85-1.98) p=0.23). No significant difference in rate of re-operation between the two groups was detected.
Conclusions: Concomitant tricuspid valve ring annuloplasty during mitral valve surgery can be safely performed without increasing mortality and morbidity risks. There is a tendency for increased rate of PPM implantation in concomitant TVA although this did not reach statistical significance. Concomitant TVA is associated with a significantly lower incidence of post-operative moderate/severe TR progression. Further prospective and RCT studies are needed to evaluate the impact of concomitant TVA on right ventricular function and long term clinical benefits.
Mitral Conclave:
Tricuspid Valve Diseases & Therapies
Image or Table
